<DOC>
	<DOCNO>NCT00401427</DOCNO>
	<brief_summary>The combination vinorelbine weekly trastuzumab produce high response rate HER2 overexpressing metastatic breast cancer ( MBC ) . The present phase 2 study plan test activity combination , trastuzumab give every 3 week , rather weekly .</brief_summary>
	<brief_title>HERVIN : Trastuzumab Vinorelbine Metastatic Breast Cancer</brief_title>
	<detailed_description>The schedule treatment include vinorelbine ( 30 mg/m2 day 1 &amp; 8 every 21 day ) trastuzumab ( 8 mg/kg day 1 6 mg/kg every 21 day ) . Vinorelbine plan maximum 9 cycle , trastuzumab continued progression . This study single-stage phase 2 design , patient eligible response evaluation require .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Histologically cytologically confirm breast cancer Stage IV No prior one prior chemotherapy metastatic disease Overexpression HER2 ( 3+ immunohistochemical exam ) amplify genetic expression cerbB2/neu ( positive Fish method ) Performance status 02 ( ECOG ) Absence measurable disease Life expectancy &lt; 3 month Concomitant malignancy malignancy within previous 5 year ( except basal cell spinocellular skin cancer situ cervical cancer adequately treat Previous treatment trastuzumab vinorelbine Neutrophils &lt; 1500/mm3 platelet &lt; 100000/mm3 haemoglobin &lt; 8 g/dl Creatinine &gt; 1.5 x value upper normal limit GOT and/or GPT &gt; 2.5 x value upper normal limit and/or bilirubin &gt; 1.5 x value upper normal limit absence liver metastasis GOT and/or GPT &gt; 5 x value upper normal limit and/or bilirubin &gt; 3 x value upper normal limit presence liver metastases Left ventricular ejection fraction &lt; 50 % ( measure ultrasound MUGA angiography ) Concomitant condition contraindicate use drug protocol Male gender Pregnancy lactationÂ· Incapacity refusal provide inform consent Inability comply followup</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>HER2 overexpression</keyword>
	<keyword>combination therapy</keyword>
</DOC>